A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Eli Lilly & Co.’s obesity drug Zepbound helped people ... Although Novo was first to market with Wegovy and its sister drug ...

(MENAFN- GlobeNewsWire - Nasdaq) Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity ... Novo Nordisk and Eli Lilly and potential ...

In December of last year, Eli Lilly directly compared the weight ... and that Zeb Bound is expected to soon seize the lead in the obesity market. There are analyses suggesting that Zeb Bound's ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

I believe orforglipron’s approval should finally lead to widespread and global availability of obesity medicines ... improve Eli Lilly’s leadership position in this market and these results ...

Shares in Eli Lilly rose sharply in pre-market trading today after the company ... an oral alternative to current injectable drugs for obesity. The results from the ACHIEVE-1 study – one of ...

Despite beating on its earnings Thursday, pharma giant Eli Lilly (LLY) suffered a nearly 12% loss in its stock, losing more than $90 billion in market cap ... on new branded obesity scripts ...

Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...

Thanks to these recent developments, Eli Lilly could take the lead in this fast-growing market. The company's ... obstructive sleep apnea in adults with obesity. In November, it announced it ...